Research programme: cancer immunotherapeutics - CARsgen

Drug Profile

Research programme: cancer immunotherapeutics - CARsgen

Alternative Names: CAR-CD19 T - CARsgen; CAR-CD19 T cells - CARsgen; CD19 Redirected Autologous Cells - CARsgen; CSG-002; CSG-004; CSG-005; CSG-007; CSG-CD19

Latest Information Update: 19 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CARsgen
  • Class CAR-T cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Gastric cancer; Glioblastoma; Haematological malignancies; Hepatocellular carcinoma; Lung cancer; Neuroblastoma; Ovarian cancer; Pancreatic cancer

Most Recent Events

  • 05 Oct 2017 Carsgen plans a phase I trial for CAR-CD19 T cells for B cell leukaemia/lymphoma (In adults, In the elderly) in China (NCT03302403)
  • 11 May 2017 CARsgen and Changhai Hospital plan a clinical pilot study for Gastric and Pancreatic cancer (Late-stage disease, Second-line therapy or greater, Metastatic disease, In adults, In the elderly) in China (IV)(NCT03159819)
  • 13 Oct 2016 CARsgen Therapeutics and RenJi Hospital plan a phase I trial for B-cell lymphoma and B-cell leukaemia in China (IV) (NCT02933775)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top